Catheter related bloodstream infections (CRBSI), also known as Central Line Associated Bloodstream Infections (CLABSI), account for a large proportion of the costs related to healthcare associated infections (HAI) in patients using medical devices, such as central venous catheters (CVC).

These infections can lead to serious complications, causing patient suffering as well as increased mortality and healthcare costs. In addition, many of these infections are treated with antibiotics, which increase the risk of emergence and spread of multi-resistant microbes. WHO estimates that antimicrobial resistance is so serious that it threatens the achievements of
modern medicine.


To address these problems, Bactiguard has developed a central venous catheter, the BIP CVC, with Bactiguard coating that reduces the risk of microbial adhesion and colonization. Bactiguard coated CVCs have been shown to reduce catheter-related infections in high-risk patients, when compared to uncoated CVCs3. The Bactiguard Infection Protection (BIP) technology is based on applying a very thin noble metal coating, consisting of gold, palladium and silver, to medical devices. The Bactiguard coating is firmly bound to the surface of the device and reduces the adhesion and growth of microbes.